These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 26707698)

  • 1. Consumer's risk in the EMA and FDA regulatory approaches for bioequivalence in highly variable drugs.
    Muñoz J; Alcaide D; Ocaña J
    Stat Med; 2016 May; 35(12):1933-43. PubMed ID: 26707698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioequivalence for highly variable drugs: regulatory agreements, disagreements, and harmonization.
    Endrenyi L; Tothfalusi L
    J Pharmacokinet Pharmacodyn; 2019 Apr; 46(2):117-126. PubMed ID: 30798390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The bioequivalence of highly variable drugs and drug products.
    Midha KK; Rawson MJ; Hubbard JW
    Int J Clin Pharmacol Ther; 2005 Oct; 43(10):485-98. PubMed ID: 16240706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Testing for bioequivalence of highly variable drugs from TR-RT crossover designs with heterogeneous residual variances.
    Kang Q; Vahl CI
    Pharm Stat; 2017 Sep; 16(5):361-377. PubMed ID: 28620937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Controlling type I error in the reference-scaled bioequivalence evaluation of highly variable drugs.
    Ocaña J; Muñoz J
    Pharm Stat; 2019 Oct; 18(5):583-599. PubMed ID: 31190418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methods to control the empirical type I error rate in average bioequivalence tests for highly variable drugs.
    Deng Y; Zhou XH
    Stat Methods Med Res; 2020 Jun; 29(6):1650-1667. PubMed ID: 31478464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two-stage designs versus European scaled average designs in bioequivalence studies for highly variable drugs: Which to choose?
    Molins E; Cobo E; Ocaña J
    Stat Med; 2017 Dec; 36(30):4777-4788. PubMed ID: 28853164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioequivalence approaches for highly variable drugs and drug products.
    Haidar SH; Davit B; Chen ML; Conner D; Lee L; Li QH; Lionberger R; Makhlouf F; Patel D; Schuirmann DJ; Yu LX
    Pharm Res; 2008 Jan; 25(1):237-41. PubMed ID: 17891552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On the leveling-off properties of the new bioequivalence limits for highly variable drugs of the EMA guideline.
    Karalis V; Symillides M; Macheras P
    Eur J Pharm Sci; 2011 Nov; 44(4):497-505. PubMed ID: 21945487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of a scaling approach for the bioequivalence of highly variable drugs.
    Haidar SH; Makhlouf F; Schuirmann DJ; Hyslop T; Davit B; Conner D; Yu LX
    AAPS J; 2008 Sep; 10(3):450-4. PubMed ID: 18726698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Exact Procedure for the Evaluation of Reference-Scaled Average Bioequivalence.
    Tothfalusi L; Endrenyi L
    AAPS J; 2016 Mar; 18(2):476-89. PubMed ID: 26831249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of bioequivalence for highly variable drugs with scaled average bioequivalence.
    Tothfalusi L; Endrenyi L; Arieta AG
    Clin Pharmacokinet; 2009; 48(11):725-43. PubMed ID: 19817502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Algorithms for evaluating reference scaled average bioequivalence: power, bias, and consumer risk.
    Tothfalusi L; Endrenyi L
    Stat Med; 2017 Nov; 36(27):4378-4390. PubMed ID: 28850696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements.
    Davit BM; Kanfer I; Tsang YC; Cardot JM
    AAPS J; 2016 May; 18(3):612-8. PubMed ID: 26943914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sample sizes for designing bioequivalence studies for highly variable drugs.
    Tothfalusi L; Endrenyi L
    J Pharm Pharm Sci; 2012; 15(1):73-84. PubMed ID: 22365089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interchangeability between Generic and Reference Products: Limits of Average Bioequivalence Methodology.
    Lechat P
    Eur J Drug Metab Pharmacokinet; 2022 Nov; 47(6):777-787. PubMed ID: 35986193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bayesian approach to average bioequivalence using Bayes' factor.
    Ghosh P; Khattree R
    J Biopharm Stat; 2003 Nov; 13(4):719-34. PubMed ID: 14584718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Scaled average bioequivalence methods for highly variable drugs: Leveling-off soft limits and the EMA's 2010 guideline (some ways to improve its type I error control).
    Muñoz J; Ocaña J; Suárez R; Millapán C
    Stat Med; 2024 Mar; 43(7):1475-1488. PubMed ID: 38316492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implementation of a reference-scaled average bioequivalence approach for highly variable generic drug products by the US Food and Drug Administration.
    Davit BM; Chen ML; Conner DP; Haidar SH; Kim S; Lee CH; Lionberger RA; Makhlouf FT; Nwakama PE; Patel DT; Schuirmann DJ; Yu LX
    AAPS J; 2012 Dec; 14(4):915-24. PubMed ID: 22972221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On statistical power for average bioequivalence testing under replicated crossover designs.
    Wan H; Chow SC
    J Biopharm Stat; 2002 Aug; 12(3):295-309. PubMed ID: 12448572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.